Evaluation of behavioral and neurochemical changes induced by ketamine in rats: Implications as an animal model of mania

Journal of Psychiatric Research

Volumn 46, Issue 12, 2012, Pages 1569-1575

  Ghedim, Fernando V ^a   Fraga, Daiane de B ^a   Deroza, Pedro F ^a   Oliveira, Mariana B ^a   Valvassori, Samira S ^a   Steckert, Amanda V ^a   Budni, Josiane ^a   Dal Pizzol, Felipe ^a   Quevedo, João ^a   Zugno, Alexandra I ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

Author keywords

Bipolar disorder; Carbonyl protein; Hyperlocomotion; Ketamine; Lithium; Mania; TBARS; Valproate

Indexed keywords

EID: 84868013966     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.08.010     Document Type: Article

References (63)

1. Aliyazicioĝlu R., Kural B., Colak M., Karahan S.C., Ayvaz S., Deĝer O. Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder. The Tohoku Journal of Experimental Medicine 2007, 273:79-87.
2. Andreazza A.C., Kapczinski F., Kauer-Sant'Anna M., Walz J.C., Bond D.J., Gonçalves C.A., et al. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. Journal of Psychiatry & Neuroscience 2009, 34:263-271.
3. Andreazza A.C., Shao L., Wang J.F., Young L.T. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Archives of General Psychiatry 2010, 67:360-368.
4. Baldessarini R.J., Tondo L., Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorder. The Journal of Clinical Psychiatry 1999, 60:77-84.
5. Banerjee U., Dasgupta A., Rout J.K., Singh O.P. Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Progress in Neuropsychopharmacology & Biological Psychiatry 2012, 37:56-61.
6. Brocardo P.S., Budni J., Pavesi E., Franco J.L., Uliano-Silva M., Trevisan R., et al. Folic acid administration prevents ouabain-induced hyperlocomotion and alterations in oxidative stress markers in the rat brain. Bipolar Disorders 2010, 12:414-424.
7. Brüning C.A., Prigol M., Luchese C., Pinton S., Nogueira C.W. Diphenyl diselenide ameliorates behavioral and oxidative parameters in an animal model of mania induced by ouabain. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2012, 38:168-174.
8. Calabrese V., Scapagnini G., Giuffrida-Stella A.M. Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochemistry Research 2003, 26:739-764.
9. Calabrese J.R., Hirschfiel R.M., Reed M. Impact of bipolar disorder on U.S. community sample. Journal Clinical Psychiatry 2001, 64:425-432.
10. Canever L., Oliveira L., D'Altoé de Luca R., Correa P.T., de B Fraga D., Matos M.P., et al. A rodent model of schizophrenia reveals increase in creatine kinase activity with associated behavior changes. Oxidative Medicine and Cellular Longevity 2010, 6:421-427.
11. Chuang D.M., Chen R.W., Chalecka-Franaszek E., Ren M., Hashimoto R., Senatorov V., et al. Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disorder 2002, 2:129-136.
12. Coyle J.T., Duman R.S. Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron 2003, 38:157-160.
13. Da-Rosa D.D., Valvassori S.S., Steckert A.V., Arent C.O., Ferreira C.L., Lopes-Borges J., et al. Differences between dextroamphetamine and methamphetamine: behavioral changes and oxidative damage in brain of Wistar rats. Journal of Neural Transmission 2012, 131:31-38.
14. De Oliveira L., Fraga D.B., De Luca R.D., Canever L., Ghedim F.V., Matos M.P., et al. Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine. Metabolic Brain Disease 2011, 26:69-77.
15. Dickerson F., Stallings C., Vaughan C., Origoni A., Khushalani S., Yolken R. Antibodies to the glutamate receptor in mania. Bipolar Disorder 2012, 14:547-553.
16. Draper H.H., Squires E.J., Mahmoodi H., Wu J., Agarwal S., Hadley M. A comparative evaluation of thiobarbituric acid methods for the determination of malondialdehyde in biological materials. Free Radical Biology & Medicine 1993, 15:353-363.
17. Duman R.S., Monteggia L.M. A neutotrophic model for stress-related mood disorders. Biological Psychiatry 2006, 12:1116-1127.
18. Einat H., Manji H.K. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biological Psychiatry 2006, 59:1160-1171.
19. Einat H., Yuan P., Gould T.D., Li J., Du J., Manji H.K., et al. The role of the extracellular signal-regulated kinase signaling pathway in mood regulation. Journal of Neuroscience 2003, 23:7311-7316.
20. El-Mallakh R.S., El-Masri M.A., Huff M.O., Li X.P., Decker S., Levy R.S. Intracerebroventricular administration of ouabain as a model of mania in rats. Bipolar Disorders 2003, 5:362-365.
21. Ellenbroek B.A., Cools A.R. Animal models with construct validity for schizophrenia. Behavioural Pharmacology 1990, 6:469-490.
22. Floyd R.A. Antioxidants, oxidative stress, and degenerative neurological disorders. Proceedings of the Society for Experimental Biology and Medicine 1999, 222:236-245.
23. Frey B.N., Andreazza A.C., Ceresér K.M.M., Martins M.R., Valvossori S.S., Réus G.Z., et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sciences 2006, 79:281-286.
24. Frey B.N., Valvassori S.S., Réus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Effects of lithium and valproate on amphetamine induced oxidative stress generation in an animal model of mania. Journal Psychiatry Neuroscience 2006, 31:326-332.
25. Goodwin F.K., Jamison K.R. Manic-depressive illness: bipolar and recurrent unipolar disorders 2003, Oxford University Press, New York. 2nd ed.
26. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biological Psychiatry 2007, 62:1310-1316.
27. Heresco-levy U. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opinion on Emerging Drugs 2005, 10:827-844.
28. Hirschfeld R.M., Lewis L., Vornik L.A. Perceptions and impact of bipolar disorder: how far have we really come? Results of National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. The Journal of Clinical Psychiatry 2003, 64:161-174.
29. Jornada L.K., Valvassori S.S., Steckert A.V., Moretti M., Mina F., Ferreira C.L., et al. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. Journal of Psychiatric Research 2011, 45:162-168.
30. Judd L.L., Akiskal H.S., Schettler P.L. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 2002, 59:530-537.
31. Kato T., Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disorders 2000, 2:180-190.
32. Kato T., Kubota M., Kasahara T. Animal models of bipolar disorder. Neuroscience and Behavioural Reviews 2007, 31:832-842.
33. Kugaya A., Sanacora G. Beyond monoamines: glutamatergic function in mood disorders. CNS Spectrums 2005, 10:808-819.
34. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochemistry and Function 2002, 20:171-175.
35. Kupfer D.J. The increasing medical burden in bipolar disorder. The journal of the American Medical Association 2005, 293(20):2528-2530.
36. Levine R.L., Williams J.A., Stadtman E.R., Shacter E. Carbonyl assays for determination of oxidatively modified proteins. Methods in Enzymology 1994, 233:346-357.
37. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. The Journal of Biological Chemistry 1951, 193:265-267.
38. Lucca G., Comim C.M., Valvassori S.S., Pereira J.G., Stertz L., Gavioli E.C., et al. Chronic mild stress paradigm reduces sweet food intake in rats without affecting brain derived neurotrophic factor protein levels. Current Neurovascular Research 2008, 5:207-213.
39. Ludtmann M.H., Boeckeler K., Williams R.S. Molecular pharmacology in a simple model system: implicating MAP kinase and phosphoinositide signalling in bipolar disorder. Seminars in cell & developmental biology 2011, 22(1):105-113.
40. Lyoo I.K., Dager S.R., Kim J.E., Yoon S.J., Friedman S.D., Dunner D.L., et al. Lithium-induced gray matter volume increase as a neural correlate of treatment response in bipolar disorder: a longitudinal brain imaging study. Neuropsychopharmacology 2010, 35:1743-1750.
41. Machado-Vieira R., Andreazza A.C., Viale C.I., Zanatto V., Cereser V., da Silva Vargas R., et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neuroscience Letters 2007, 421:33-36.
42. Maeng S., Zarate J.R. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Current Psychiatry Reports 2007, 9:467-474.
43. Manji H.K., Chen G.P.K.C. MAP kinases and bcl-2 family of proteins as long-term targets for mood stabilizers. Molecular Psychiatry 2002, 7:46-56.
44. Manning J.S., Haykal R.F., Connor P.D. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Comprehensive Psychiatry 1997, 38:102-108.
45. Mccullumsmith R.E., Kristiansen L.V., Beneyto M., Scarr E., Dean B., Meador-Woodruff J.H. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Research 2007, 1127:108-118.
46. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. Journal of Neuroscience 1997, 17:2921-2927.
47. Molina M.F., Sanchez-Reus I., Iglesias I., Benedi J. Quercetin, a flavonoid antioxidant, prevents and protects against ethanol-induced oxidative stress in mouse liver. Biological & Pharmaceutical Bulletin 2003, 26:1398-1402.
48. Ozcan M.E., Gulec M., Ozerol E., Polat R., Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. International Clinical Psychopharmacology 2004, 19:89-95.
49. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research 2003, 121:109-122.
50. Rao J.S., Harry G.J., Rapoport S.I., Kim H.W. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Molecular Psychiatry 2010, 15:384-392.
51. Rao J.S., Kellom M., Reese E.A., Rapoport S.I., Kim H.W. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. Journal of Affective Disorders 2012, 136:63-71.
52. Rezin G.T., Cardoso M.R., Goncalves C.L., Scaini G., Fraga D.B., Riegel R., et al. Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochemistry International 2008, 53:395-400.
53. Ricke A.K., Snook R.J., Anand A. Induction of prolonged mania during ketamine therapy for reflex sympathetic dystrophy. Biological Psychiatry 2011, 70:13-14.
54. Riegel R.E., Valvassori S.S., Elias G., Réus G.Z., Steckert A.V., de Souza B., et al. Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochemistry International 2009, 55:491-495.
55. Riegel R.E., Valvassori S.S., Moretti M., Ferreira C.L., Steckert A.V., de Souza B., et al. Intracerebroventricular ouabain administration induces oxidative stress in the rat brain. International Journal of Developmental Neuroscience 2010, 28:233-237.
56. RorickKehn L.M., Johnson B.G., Knitowski K.M., Salhoff C.R., Witkin J.M., Perry K.W., et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 2007, 193:121-136.
57. Schoepp D.D., Marek G.J. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?. Current Drug Targets CNS and Neurological Disorders 2002, 1:215-222.
58. Spearing M. Bipolar disorder 2001, NIH Publication, Washington, DC.
59. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Reviews Drug Discovery 2005, 4:131-144.
60. Valvassori S.S., Frey B.N., Martins M.R., Reus G.Z., Schimidtz F., Inacio C.G., et al. Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats. Behavioural Pharmacology 2007, 3:205-212.
61. Valvassori S.S., Rezin G.T., Ferreira C.L., Moretti M., Gonçalves C.L., Cardoso M.R., et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. Journal of Psychiatry Research 2010, 44:903-909.
62. Wang J.F., Azzam J.E., Young L.T. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience 2003, 116:485-489.
63. Yatham L.N., Kennedy S.H., O'donovan C. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disorder 2005, 7:5-69.